Mohammad Atiq

MedicineChemistryBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors”.

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2483

N/A

0DataRank · unranked

21 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.347

N/A

0DataRank · unranked

8 citations

Arnab Ghosh, Subhiksha Nandakumar, Joshua Armenia, Ying Z. Mazzu, Mohammad Atiq +6 more

Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.150

N/A

0DataRank · unranked

0 citations

Goutam Chakraborty, Subhiksha Nandakumar, Ying Z. Mazzu, Konrad H. Stopsack, Yuki Yoshikawa +3 more

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5096

N/A

0DataRank · unranked

3 citations

Marijo Bilušić, Fatima Karzai, Lisa M. Cordes, Julius Strauss, Houssein Abdul Sater +10 more

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e17044

N/A

0DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Helen Owens +8 more

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.093

N/A

0DataRank · unranked

4 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.130

N/A

0DataRank · unranked

3 citations

Mohammad Atiq, Renee N. Donahue, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +11 more

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17033

N/A

0DataRank · unranked

3 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more

Emerging treatment options for prostate cancer

Expert Review of Anticancer Therapy(2023)10.1080/14737140.2023.2208352

N/A

0DataRank · unranked

19 citations

Elias Chandran, Fatima Karzai, Ravi A. Madan, Jeanny B. Aragon‐Ching, Mohammad Atiq

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Frontiers in Oncology(2023)10.3389/fonc.2023.1126476

N/A

0DataRank · unranked

1 citations

Danielle M. Pastor, Fatima Karzai, Amy Hankin, Barış Türkbey, Lisa M. Cordes +5 more

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.207

N/A

0DataRank · unranked

0 citations

Meghali Goswami, Renee N. Donahue, Mohammad Atiq, Fatima Karzai, Marijo Bilušić +13 more

Data from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

(2023)10.1158/1078-0432.c.6530694

N/A

0DataRank · unranked

0 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

Data from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

(2023)10.1158/1078-0432.c.6530694.v1

N/A

0DataRank · unranked

0 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5101

N/A

0DataRank · unranked

0 citations

Liza Lindenberg, Esther Mena Gonzalez, Barış Türkbey, Fatima Karzai, Megan Hausler +8 more